Literature DB >> 16903923

Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.

Sayuri Yamazaki1, Kayo Inaba, Kristin V Tarbell, Ralph M Steinman.   

Abstract

Thymic derived naturally occurring CD25+ CD4+ T regulatory cells (Tregs) suppress immune responses, including transplantation. Here we discuss the capacity of dendritic cells (DCs) to expand antigen-specific Tregs, particularly polyclonal Tregs directed to alloantigens. Initial studies have shown that mature DCs are specialized antigen-presenting cells (APCs) for expanding antigen-specific CD25+ CD4+ Tregs from TCR transgenic mice. When triggered by specific antigen, these Tregs act back on immature DCs to block the upregulation of CD80 and CD86 costimulatory molecules. More recently, DCs have been used to expand alloantigen-specific CD25+ CD4+ Tregs from the polyclonal repertoire in the presence of interleukin-2 (IL-2). Allogeneic DCs are much more effective than allogeneic spleen cells for expanding CD25+ CD4+ Tregs. The DC-expanded Tregs continue to express high levels of Foxp3, even without supplemental IL-2, whereas spleen cells poorly sustain Foxp3 expression. When suppressive activity is tested, relatively small numbers of DC-expanded CD25+ CD4+ Tregs exert antigen-specific suppression in the mixed leukocyte reaction (MLR), blocking immune responses to the original stimulating strain 10 times more effectively than to third party stimulating cells. DC-expanded Tregs also retard graft versus host disease (GVHD) across full major histocompatibility complex (MHC) barriers. In vitro and in vivo, the alloantigen-specific CD25+ CD4+ Tregs are much more effective suppressors of transplantation reactions than polyclonal populations. We suggest that the expansion of Tregs from a polyclonal repertoire via antigen-presenting DCs will provide a means for antigen-specific control of unwanted immune reactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16903923     DOI: 10.1111/j.0105-2896.2006.00422.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  86 in total

1.  IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells.

Authors:  Xiaoli Xu; Ping Zou; Lijuan Chen; Guannan Jin; Hao Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

2.  Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.

Authors:  Daniela Giordano; Chang Li; Mehul S Suthar; Kevin E Draves; Daphne Y Ma; Michael Gale; Edward A Clark
Journal:  J Leukoc Biol       Date:  2010-12-22       Impact factor: 4.962

3.  Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance.

Authors:  Bin-Quan Wang; Chun-Ming Zhang; Wei Gao; Xu-Feng Wang; Hai-Li Zhang; Ping-Chang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

Review 4.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

5.  Adoptive T Regulatory Cell Therapy for Tolerance Induction.

Authors:  Cecilia Cabello-Kindelan; Shane Mackey; Allison L Bayer
Journal:  Curr Transplant Rep       Date:  2015-06-01

6.  Allogeneic apoptotic thymocyte-stimulated dendritic cells expand functional regulatory T cells.

Authors:  Thaís Boccia da Costa; Luiz R Sardinha; Rafael Larocca; Jean P S Peron; Luiz V Rizzo
Journal:  Immunology       Date:  2011-03-01       Impact factor: 7.397

7.  PU.1-silenced dendritic cells prolong allograft survival in rats receiving intestinal transplantation.

Authors:  Xing-Wei Xu; Bo-Wen Ding; Chuan-Rong Zhu; Wu Ji; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 9.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

10.  CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells.

Authors:  Sayuri Yamazaki; Diana Dudziak; Gordon F Heidkamp; Christopher Fiorese; Anthony J Bonito; Kayo Inaba; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.